论文部分内容阅读
目的:探讨氟西汀联合匹维溴铵治疗腹泻型肠易激综合征(IBS)的临床疗效。方法:选取2013年4月至2016年3月宜春市人民医院治疗的189例腹泻型IBS患者,根据不同治疗方案分为两组,观察组应用氟西汀联合匹维溴铵治疗,并根据具体症状进行对症治疗,对照组仅应用对症治疗。记录两组临床症状改善情况、治疗不良反应发生情况以及汉密顿抑郁量表(HAMD)评分,并进行分析。结果:观察组缓解率达89.58%显著高于对照组的60.22%,差异具有统计学意义(P<0.05);观察组治疗期间出现一过性乏力,头晕症状者2例,不良反应发生率2.15%,对照组所有患者均无不良反应表现,但两组不良反应发生率比较差异无统计学意义(P>0.05);两组HAMD评分在治疗前对比差异无统计学意义(P>0.05);在治疗后,观察组的评分显著低于对照组,且差异具有统计学意义(P<0.05)。结论氟西汀联合匹维溴铵治疗腹泻型IBS安全有效。
Objective: To investigate the clinical efficacy of fluoxetine and pinaverium bromide in the treatment of diarrhea-predominant irritable bowel syndrome (IBS). Methods: A total of 189 IBS patients with diarrhea treated by Yichun People’s Hospital from April 2013 to March 2016 were selected and divided into two groups according to the different treatment regimens. The observation group was treated with fluoxetine combined with piroxicam, Symptomatic treatment of symptoms, the control group only symptomatic treatment. The improvement of clinical symptoms, the incidence of adverse reactions and the HAMD score were recorded and analyzed. Results: The remission rate of the observation group was 89.58%, which was significantly higher than that of the control group (60.22%), the difference was statistically significant (P <0.05) .There were two cases of transient fatigue, dizziness, and adverse reactions in observation group during treatment %. All the patients in the control group showed no adverse reactions, but there was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). There was no significant difference in HAMD score between the two groups before treatment (P> 0.05). After treatment, the score of the observation group was significantly lower than that of the control group, and the difference was statistically significant (P <0.05). Conclusion Fluoxetine combined with pinaverium bromide is safe and effective in the treatment of IBS.